킵스파마
Financials
Valuation Metrics
킵스파마's Market Cap is ₩1014B. At end of 2025 it was ₩2088B. Ranked #1180 of 2,410 in KR market (top 49%), #626 of 1,631 on KOSDAQ (top 38%), #129 of 214 in Semiconductors & Semiconductor Equipment (top 60%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 101.39B KRW | KR#1,180/2,410 Sec#129/214 |
| Revenue | 220.48B KRW | KR#973/2,410 Sec#68/214 |
| Net Income | -13.02B KRW | KR—/2,410 Sec—/214 |
| Total Assets | 233.88B KRW | KR#1,198/2,410 Sec#98/214 |
| Net Assets | 79.65B KRW | KR#1,592/2,410 Sec#140/214 |
| Employees | 27 | KR#2,207/2,410 Sec#204/214 |
| Value | ||
| P/B | 1.27x | KR#1,740/2,410 Sec#104/214 |
| P/S | 0.46x | KR#929/2,410 Sec#35/214 |
| FCF Yield | -46.21% | KR—/2,410 Sec—/214 |
| Profitability | ||
| ROE | -16.34% | KR#2,043/2,410 Sec#180/214 |
| ROA | -5.56% | KR#1,955/2,410 Sec#168/214 |
| Op. Margin | -0.27% | KR#1,625/2,410 Sec#136/214 |
| Revenue Growth | 48.61% | KR#215/2,410 Sec#37/214 |
| Financial Health | ||
| Debt Ratio | 193.65% | KR#2,078/2,410 Sec#194/214 |
| Total Debt | 94.56B KRW | KR#750/2,410 Sec#43/214 |
| FCF | -46.85B KRW | KR#2,065/2,410 Sec#191/214 |
| Cash | 11.54B KRW | KR#1,613/2,410 Sec#151/214 |
| Current Ratio | 1.06x | KR#1,643/2,410 Sec#157/214 |
| Performance | ||
| 1Y Return | -44.57% | KR#1,759/2,410 Sec#169/214 |
| 1M Return | -27.55% | KR#1,730/2,410 Sec#107/214 |
| From 52W High | -60.79% | KR#1,635/2,410 Sec#143/214 |
| 1Y MDD | -59.44% | KR#1,375/2,410 Sec#80/214 |
| Trading | ||
| Volume | 32,909 shares | KR#1,187/2,410 Sec#153/214 |
| Trading Value | 163.6M KRW | KR#1,218/2,410 Sec#153/214 |
| Foreign Own. | 2.67% | KR#1,398/2,410 Sec#149/214 |
| Per Share | ||
| EPS | -648 KRW | KR—/2,410 Sec—/214 |
| BPS | 3,967 KRW | KR#1,690/2,410 Sec#152/214 |
Company Info
KeepsPharma, established in 2000 and headquartered in Hwaseong-si, Gyeonggi-do, transitioned to the pharmaceutical and biotechnology sector in 2025, following its KOSDAQ listing in 2017. The company's primary activities include the manufacturing and sales of specialized medicines, development of oral peptide drug delivery platforms, anticancer treatments, and medical devices. KeepsPharma is also diversifying its business through the expansion of CDMO and CMO services, LFP recycling, and the localization of micro OLED equipment and fine metal masks.